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Visual Abstract 
Key Question: Does the biomarker suPAR have value in predicting postop 
complications in patients following cardiac surgery? 
Key Findings: suPAR was predictive for prolonged hospital and ICU stay at all 
timepoints, including preop, and compared favourably to other scoring tools. 
Take Home Message: In cardiac surgery patients, suPAR is a predictor of postop 
complications that can help perioperative clinical decision making. 
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Abstract 
Objectives: Soluble urokinase plasminogen activator receptor (suPAR) is a 
biomarker that has been implicated in several cardiac pathologies and has been 
shown to be elevated in critically-ill populations. We measured plasma suPAR in a 
cohort of cardiac surgical patients to evaluate its ability to predict prolonged 
intensive care unit (ICU) and hospital length of stay and development of 
complications following surgery. We compared suPAR against Euroscore II and CRP.   
Methods: Ninety patients undergoing cardiac surgery were recruited with samples 
taken preoperatively and on postoperative days 1, 2 and 3. suPAR was measured 
using enzyme-linked immunosorbent assay. Area under the receiver operating 
characteristic curve (AUROC) was used to test predictive capability of suPAR. 
Comparison was made with Euroscore II and C-reactive protein (CRP).  
Results: suPAR increased over time (p<0.001) with higher levels in patients 
requiring prolonged ICU and hospital stay, and prolonged ventilation (p<0.05). 
suPAR was predictive for prolonged ICU and hospital stay, and prolonged ventilation 
at all time-points (AUROC 0.66-0.74). Interestingly this association was also 
observed preoperatively, with preoperative suPAR predicting prolonged ICU (AUROC 
0.66), and hospital stay (AUROC 0.67) and prolonged ventilation (AUROC 0.74). 
The predictive value of preoperative suPAR compared favourably to EuroSCORE II 
and CRP. 
Conclusions: suPAR increases following cardiac surgery and levels are higher in 
those who require prolonged ICU stay, prolonged hospital stay and prolonged 
ventilation. Preoperative suPAR compares favourably to EuroSCORE II and CRP in 
prediction of these outcomes. suPAR could be a useful biomarker in predicting 
outcome following cardiac surgery, helping inform clinical decision making. 
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 ICU – Intensive Care Unit  
 suPAR – Soluble Urokinase Plasminogen Receptor 
 CRP – C Reactive Protein 
 AUROC – Area Under the Receiver Operator Curve  
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Introduction 
Patients undergoing cardiac surgery are at risk of multisystem postoperative 
complications1 resulting in prolongation of intensive care unit (ICU) admission2 and 
hospital stay.3 The ability to predict either preoperatively, or early postoperatively, 
those patients at increased risk of complications would aid clinical decision-making. 
A reliable prognostic biomarker4 would enable identification of patients at increased 
risk, allowing them to receive additional monitoring and earlier intervention. 
Conversely, identification of patients unlikely to require extra support would allow 
these patients to be triaged to a fast-track recovery. 
Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the 
leukocyte membrane-bound urokinase plasminogen activator receptor (uPAR)5 and 
has been linked to plasminogen activation, pericellular proteolysis, and 
chemotaxis.5,6  
 suPAR is a novel biomarker that has been shown to have diagnostic 
and predictive value in cardiovascular disease,7, 8 the critically ill,9, 10 and patient’s 
with  sepsis.11,12   
We hypothesised suPAR would increase following cardiac surgery and would be 
useful to identify patients requiring a prolonged stay in hospital and/or ICU. 
Furthermore, we compared the discriminative capability of suPAR against C-
Reactive protein (CRP) and Euroscore II, both of which are measured and 
calculated perioperatively, to assess suPAR’s potential clinical applicability against 
established methods.  
EuroSCORE II is a scoring system used prior to cardiac surgery to provide an 
estimate of predicted mortality.13 It considers various patient-dependent factors, 
such as cardiac and renal function, as well as surgical factors, and quantifies the 
overall risk of death. It is intuitive that patients at higher risk of death have higher 
risk of increased intensive care requirement and EuroSCORE II has been 
demonstrated to predict prolonged ICU stay.14 CRP is widely measured in this 
patient population and is used to identify patients mounting an inflammatory 
response and determine those at risk of complications such as infection. For these 
reasons, EuroSCORE II and CRP were compared to suPAR.  
 
Finally, we wanted to assess whether a combined model integrating commonly used 
clinical information with inflammatory biomarkers would have a greater value in 





Trial Enrolment and Ethics Approval  
This study is a post-hoc analysis of a previous study examining acute kidney injury 
in patients undergoing cardiac surgery. The trial was registered in April 2012 at 
ClinicalTrials.Gov (Trial number NCT01573104). Ethical approval for this study 
(Ethic committee number: 12/WS/0179) was provided by the West of Scotland 
Research Ethics Service on the 21st of August 2012. A substantial amendment to 
allow the additional analyses was submitted on the 26th of September 2014 and 
approved by the same ethics committee on the 27th of April 2016. With informed 
consent, blood samples were collected from patients undergoing cardiopulmonary 
bypass cardiac surgery at the Golden Jubilee National Hospital between November 
2011 and January 2014.  
Data Collection 
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Exclusion criteria for the primary study were; patient/surgical refusal, preoperative 
renal replacement, emergency procedures, age <18 or >90 years, pregnancy, the 
use of ventricular-assist devices, severe chronic renal failure (defined as eGFR 
<30mL/min/1.73m2) and impaired patient capacity to consent. 
Baseline information was collected on admission about co-morbidity status, from 
which EuroSCORE II13 was calculated. Intraoperative data were collected from the 
recall AIMS electronic anaesthetic charting system (Informatics Clinical Information 
Systems Limited, Glasgow) and postoperative data from the hospitals ICU clinical 
information system (Centricity CIS; GE Healthcare©, Buckinghamshire, UK). 
In accordance with previous studies, prolonged ICU stay was defined as over 48 
hours14 and prolonged hospital stay was defined as 12 days or greater.15 Often 
patients are discharged from intensive care or hospital for logistical rather than 
clinical reasons, at ‘set times’, such as following the morning ward round, which can 
confound the use of length of stay data as a continuous variable. To counter this, 
these variables were dichotomized to highlight patients that had deviated from 
normal recovery and required prolonged stays.  
A composite endpoint of complications was used; surgical re-operation, stroke, 
deep sternal wound infection, postoperative renal failure, prolonged ventilation16 
and atrial fibrillation. Surgical re-operation, stroke and deep sternal wound infection 
were included if documented in the hospital’s cardiac surgery database (Cardiac, 
Cardiology, and Thoracic Health Information System; CaTHi, Amor Group, Renfrew, 
Scotland). In line with previous studies, renal failure was defined as acute kidney 
injury network17 stage 1 or greater18 and prolonged ventilation was defined as over 
24 hours.19,20 
Blood samples were collected before induction of anaesthesia and were also 
collected on the morning of postoperative days 1, 2 and 3. Samples were 
centrifuged, frozen and stored at -80°C until analysis. suPAR was measured in 
duplicate using a commercially available solid phase enzyme linked immunosorbent 
assay (suPARnostic®, Virogates, Denmark) according to the manufacturer’s 
instructions. The within-batch coefficient of variation (CV) was 6.2%, whilst the 
between-batch CV was 11.8%. 
CRP was determined as a routine clinical sample by an enhanced 
immunoturbidimetric assay run on a Roche Cobas 6000 analyser. The reference 
range is <10mg/L, with a lower limit of detection of 1.0 mg/L and a CV of 1.7%. 
 
Statistical Analysis 
Analysis was undertaken using SPSS® (version 22, IBM, Armonk, NY). Variables 
were visually inspected and tested for normality using the Shapiro-Wilk test. 
Categorical data are presented as frequency(%) and continuous data are presented 
as mean(SD) or median(IQR) as appropriate. 
Multiple comparisons across time-points were performed using repeated measures 
ANOVA or Friedman’s test. Pairwise comparisons were performed using Wilcoxon 
signed rank test or a paired T-test with appropriate Bonferroni-adjusted p-values to 
avoid type 1 errors. Comparisons between independent groups were performed 
using Student’s T-test or Mann-Whitney U-test; adjustment for multiple testing was 
not applied. Statistical significance was determined as p<0.05.  
The area under the receiver operator curve (AUROC) was calculated to evaluate the 
discriminative capability of variables for predicting patients who would require 
prolonged ICU or hospital stay or who would develop complications. Sensitivity, 
specificity and positive and negative predictive values were calculated according to 
optimum cut off points defined as the point at which the sum of sensitivity and 
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specificity were maximal (Youden’s Index21). Multivariable logistic regression was 
used to develop a model incorporating preoperative suPAR and EuroSCORE II, with 
AUROC used to evaluate its discriminative capability. 
This manuscript adheres to the STARD guidelines where appropriate. 
Results 
Ninety patients were recruited. Of the original cohort, two patients had their 
operations cancelled after recruitment for clinical reasons, and no blood samples 
were obtained in a further five patients; these patients were excluded from 
analysis. The median age was 66 years. The median for EuroSCORE II was 1.2%, 
ventilation time was 7 hours, ICU length of stay was 23 hours and hospital length 
of stay was 7 days (Table 1). 
Seventeen patients (19.3%) had a prolonged ICU stay and 23 (26.1%) had a 
prolonged hospital stay. Those with a prolonged hospital stay were older 
(p<0.001), had a longer cardiopulmonary bypass time (p=0.004), had a longer 
aortic cross clamp time (p=0.027), and had a longer ICU stay (p=0.002) than 
those who did not. There was no difference in demographics between those having 
a longer ICU stay and those who did not (Table 2).  
suPAR was higher at all postoperative time-points compared with baseline (Figure 
1a). There were differences in suPAR levels both preoperatively and postoperative 
days 1 and 2 between those patients requiring a longer stay in the ICU and those 
who did not (Figure 2a). There were also significant differences in suPAR levels at 
all time-points between those patients who stayed longer in hospital and those who 
did not (Figure 2b).  
CRP levels were higher at all postoperative time-points compared with baseline 
(Figure 1b). There was no difference in CRP levels at any timepoint between those 
patients who required prolonged ICU and those who did not (Figure 2d). There were 
differences in CRP levels on postoperative day 2 between those patients requiring 
prolonged hospital and those that that did not, but not at other timepoints (Figure 
2e).  
Plasma suPAR levels preoperatively and postoperative day 2 were significant 
predictors of increased length of ICU and hospital stay, respectively. The predictive 
value of preoperative suPAR compared favourably to EuroSCORE II and CRP (Table 
3, Figure 3a and 3b).   
For predicting increased time in ICU, the optimum cut off point was for preoperative 
suPAR as identified by ROC curve analysis with a concentration of 1.96ng/mL, 
giving a sensitivity of 52.9% and a specificity of 79.7%. This corresponded to a 
positive predictive value of 30.8% and a negative predictive value of 90.7%. For 
predicting a prolonged hospital stay, the optimum cut off point was for 
postoperative day two suPAR with a concentration of 2.37ng/mL, sensitivity 63.2%, 
specificity 81.5%, positive predictive value (PPV) 54.5%, negative predictive value 
(NPV) 86.3%. 
Complications 
At least one of the composite complications developed in 40(45.5%) of the 88 
patients: 31(35.2%) developed new onset atrial fibrillation, 16(18.2%) developed 
postoperative renal failure with 5(5.6%) patients requiring renal replacement 
therapy, eight(9.1%) required prolonged ventilation, six(6.8%) required re-
operation, three(3.4%) had a deep sternal wound infection and one patient had 
prolonged neurological dysfunction. One patient died, equating to a mortality of 
1.1% - for the purposes of analysis this patient was treated as having a prolonged 
ICU and hospital stay. There was no difference in EuroSCORE II or suPAR levels at 
any time-point between those patients who developed a composite complication 
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and those who did not. Median CRP levels were higher in patients who went onto 
develop complications on postoperative days 1 and 2 (Figure 2f).  
In post-hoc analyses, association between individual complications and suPAR and 
CRP levels were analysed. Patients requiring prolonged ventilation had higher levels 
of suPAR preoperatively and at all postoperative time-points (Figure 2c).  
Preoperative suPAR was predictive of prolonged ventilation with an AUROC of 0.74 
(Table 3). The optimum cut off point for preoperative suPAR as identified by AUROC 
analysis was a concentration of 1.40ng/mL, sensitivity 100%, specificity 46.6%, 
PPV 17.1% and NPV 100%. There was no difference in suPAR levels between 
patients developing any of the other individual complications compared with those 
who did not.  
When CRP was analysed, levels were higher preoperatively in patients who 
developed AF (3mg/L compared with 1mg/L; p=0.002). This difference was present 
on postoperative day 1 (69mg/L compared with 47mg/L; p=0.001) and 
postoperative day 2 (179mg/L compared with 145mg/L; p=0.021). There was no 
difference in CRP levels between those patients developing any of the other 
individual complications compared with those who did not.  
Surgical Procedure 
suPAR levels were compared between the 56 patients who had coronary artery 
bypass grafting (CABG) and the 32 patients who had more complex cardiac 
surgeries (Table 1). Those patients who had more complex procedures had higher 
levels of suPAR on postoperative day 1 (2.37ng/mL compared with 1.57ng/mL; 
p=0.002), postoperative day 2 (2.42ng/mL compared with 1.86ng/mL; p=0.004) 
and on postoperative day 3 (2.77ng/mL compared with 1.85ng/mL; p=0.009), but 
not at baseline (1.81ng/mL compared with 1.44ng/mL; p=0.18). There was no 
difference in CRP levels at any timepoint. 
Combined Model 
A combined model of EuroSCORE II and preoperative suPAR levels produced similar 
AUROC to preoperative suPAR levels alone (Table 3). 
 
Discussion  
suPAR increases following cardiac surgery and is higher in patients requiring longer 
stays in the ICU and hospital and in those ventilated for more than 24 hours. This 
difference in suPAR concentrations was present preoperatively and compared 
favourably to EuroSCORE II and CRP.  
We found suPAR was elevated from baseline at all postoperative timepoints. A 
study by Gozdzik and colleagues,22 did not find elevated suPAR levels following 
cardiac surgery. This discrepancy in results could be explained by the difference in 
time frames over which suPAR was investigated, and the patient populations. 
Gozdzik and colleagues studied 60 patients undergoing isolated CABG surgery, 
whilst we included patients undergoing a variety of cardiac surgery procedures. We 
found those patients having CABG surgery only had lower suPAR postoperatively 
compared with those undergoing more complex procedures. Our study 
demonstrated a sustained rise in suPAR that was apparent on postoperative day 1, 
and beyond. This may not have been seen in Gozdzik and colleague’s study22 which 
looked at levels up to 24 hours only.  
suPAR was higher in patients requiring prolonged ICU and hospital stay and 
prolonged ventilation compared with those that did not; unexpectedly this 
difference was demonstrated preoperatively. Increases in suPAR are associated with 
immune system activation6 suggesting these patients had higher levels of 
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inflammation at baseline. Some patients may have underlying co-morbidities which 
contribute to higher suPAR levels preoperatively and predispose to a more 
complicated postoperative course. For example, suPAR has been shown to be 
higher in those with coronary artery disease with levels increasing in parallel with 
severity of disease;25 it is plausible that those patients requiring prolonged stay and 
ventilation could have more severe disease at baseline, explaining the higher suPAR 
and poorer outcome.  
A recent study by Hodges and colleagues26 demonstrated that preoperative suPAR 
levels predicted complications and mortality following aortic valve replacement. Our 
study provides further evidence of the value of preoperative suPAR levels in 
predicting outcomes following cardiac surgery. 
Interestingly, CRP levels were not elevated in those who went on to require 
prolonged stays preoperatively or on postoperative days 1 and 3. CRP can take 2-3 
days for levels to peak after a surgical insult27 and this delay can make it difficult to 
differentiate between patients developing complications and those demonstrating a 
‘normal’ response. It is possible that suPAR is a faster-reacting inflammatory 
biomarker, and therefore a better early discriminator, compared to CRP with values 
closer to peak on postoperative day 1.  
In the current study, EuroSCORE II was higher in patients who had prolonged 
hospital stay but performed poorly in predicting prolonged ICU stay (AUROC 
0.55)(Table3, Figure 3). A combined model, using preoperative suPAR and 
EuroSCORE II was better at predicting these outcomes than EuroSCORE alone. 
However, the predictive capability of the combined model was driven by suPAR 
(See Supplementary Table 1).  
The composite of complications used in our study was based upon a list of serious 
complications following cardiac surgery as defined by the Society of Thoracic 
Surgeons,16 with the addition of atrial fibrillation which has been shown to 
significantly affect mortality and morbidity.28 To further explore the apparent 
paradox that suPAR is predictive of prolonged intensive care and hospital stay, but 
not associated with postoperative complications, whilst CRP is not predictive of 
prolonged stay but is associated with complications, we conducted a post-hoc 
analysis of suPAR and CRP against individual complications.  
Elevated suPAR was predictive only for prolonged ventilation. Geboers and 
colleagues examined the ability of suPAR to predict outcomes of patients admitted 
to ICU with acute respiratory distress syndrome, observing higher levels in those 
with more severe disease.29 It is plausible, therefore, that the association between 
suPAR and prolonged ventilation reflects the development of lung injury. As this 
relationship between suPAR and duration of mechanical ventilation was also 
apparent preoperatively, we suggest suPAR may also serve as a predictor of 
susceptibility to lung injury rather than simply a measure of disease severity. 
Although the positive predictive value of suPAR in identifying patients who go on to 
require prolonged mechanical ventilation was poor (17.1%), the high negative 
predictive value (100%) was such that preoperative measurement of suPAR could 
help identify those patients unlikely to require prolonged ventilation. These patients 
could therefore be suitable for triage to fast-track recovery programs; an area of 
growing interest and study in the elective cardiac surgery population.30 
When assessing CRP, we found higher levels postoperatively were associated with 
the development of atrial fibrillation. Although a common complication (35% of 
patients in this study), atrial fibrillation following cardiac surgery often responds 
promptly to medical management and therefore the presence of this complications 
would not necessarily prolong intensive care or hospital stay, explaining the lack of 
association observed.  
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To our knowledge, this is one of the largest studies examining suPAR in patients 
undergoing various types of cardiac surgeries and to describe the use of suPAR to 
predict outcomes. Given its retrospective nature, and the number of comparisons 
made the results of this study must be considered 'hypothesis generating' to 
support planning of subsequent, prospective studies. Further, the relatively small 
sample size of 90 patients and moderate predictive capability of suPAR make it 
difficult to come to concrete conclusions on the ability of this biomarker to predict 
prolonged stay and complications. It would be therefore informative to examine any 
additional predictive value of plasma suPAR in combination with other potential 
clinical predictors enabling robust multivariable analysis and greater predictive 
capability.  
Conclusion 
We found that suPAR levels increased after cardiac surgery and that high suPAR 
levels, both pre and postoperatively, were associated with prolonged ICU stay, 
prolonged hospital stay and prolonged duration of ventilation. In addition, suPAR 
compared favourably to EuroSCORE II and CRP in predicting these outcomes. The 
next step is to explore the applicability and effectiveness of suPAR as a predictive 
biomarker in conjunction with other currently utilised clinical prediction scores in 
patients undergoing cardiac surgery in a larger study. The aim of this would be to 
assess whether suPAR could improve prediction of outcomes in combination with 
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Figure Legends  
Figure 1 – Perioperative levels of (A) Soluble Urokinase Plasminogen Activator 
Receptor (suPAR) and (B) C-Reactive Protein (CRP). Preoperative baseline (PreOp), 
Postoperative Day 1 (POD1), Day 2 (POD2), and Day 3 (POD3). Bars demonstrate 
differences between two time points (Wilcoxon Signed-Rank test with applied 
Bonferroni adjustment) (*p<0.05; **p<0.01)  
 
Figure 2 – Different levels of biomarkers and outcomes: Soluble Urokinase 
Plasminogen Activator (suPAR) levels between (A) Patients that required a 
Prolonged Intensive Care Unit Length of Stay (PICULOS) and those that did not 
(Non-PICULOS) (B) Patients that required a Prolonged Hospital Length of Stay 
(PHLOS) and those that did not (Non-PHLOS) and (C) Patients that required a 
Prolonged Ventilation and those that did not; C-reactive Protein (CRP) levels 
between (D) Patients that required a Prolonged Intensive Care Unit Length of Stay 
(PICULOS) and those that did not (Non-PICULOS) © Patients that required a 
Prolonged Hospital Length of Stay (PHLOS) and those that did not (Non-PHLOS) 
and (F) Patients that developed complications and those that did not (No-
Complications) over time-points: Preoperative (PreOp), Postoperative Day 1 
(POD1), Day 2 (POD2) and Day 3 (POD3). Bars demonstrate differences between 
groups (Mann-Whitney U Test) (*p<0.05;**p<0.01) 
 
Figure 3 – Receiver Operator Characteristic Curves demonstrating the ability of 
Preoperative suPAR, labelled “PreOp suPAR”, and EuroSCORE II to predict patients 
that will require (A) Prolonged Intensive Care Unit Length of Stay (PICULOS) (B) 
Prolonged Hospital Length of Stay (PHLOS) and (C) Prolonged Ventilation. Area 






Table 1 – Baseline patient characteristics  
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Characteristics All Patients 
(n=88) 
Age (Years) 66 (59,72) 
Female Gender n (%) 19 (21.6) 
Weight (Kg) 81 (SD:15.8) 
EuroSCORE II  1.2 (0.71,1.57) 
Actual Mortality (%) 1 (1.1) 
Cardiovascular Co-




Left Main Stenosis  



















CPB Time (Min) 84 (66,112.5) 
Aorta Clamp Time (Min) 58 (40.5,74.5) 
Surgical time (Min) 202.5 (180,255) 
Ventilation Duration (Hr) 7 (4.1,12.4) 
Intensive Care Unit Stay (Hr) 23 (21.5,46) 
Hospital stay (Days) 7 (6,12) 
Data presented as Median (IQR), mean (SD:) or frequency (%) 
MI= Myocardial Infarction, CPB= Cardiopulmonary Bypass CABG= 
Coronary Artery Bypass Graft, AVR= Aortic Valve Repair, MVR= 
Mitral Valve Repair, Other= Unspecified, MVR + CABG, MVR + 
Foramen Ovale Closure, AVR + Ascending Aortic Aneurysm Repair 
aCardiovascular comorbidities refers to previous MI, Hypertension, 










Table 2 – Key Group Characteristics and Variations 




















Age (Years) 69(51,78) 66(59,72) 71(68,77)†† 63(57,70)†† 68(51,71) 66(59,73) 
EuroSCORE II (%) 1.2(0.82,1.62) 1.1(0.71,1.59) 1.3(0.97,2.09)† 0.99(0.68,1.47)† 1.36(0.81,4.55) 1.14(0.71,1.49) 






Aorta Clamp Time (Min) 70(39,75) 56(41,74) 70(56,81)† 51.5 (37,72)† 74.5(73,122.3)‡ 56(39.5,72)‡ 




Ventilation Duration (Hr) 14.5(7,45.8)** 6.5(4,9)** 11.5(7,32)†† 5.5(4,8.8)†† 45.8(32.3,59)‡‡ 6.5(4,9.8)‡‡ 











Hospital Stay (Days) 13(8.5,15)** 6 (6,9)** 14(13,16)†† 6 (6,7)†† 14(11.5,26.5)‡‡ 7(6,10)‡‡ 
Data presented as Median (IQR)  
Symbols denote a difference between Prolonged ICU Stay vs Non-Prolonged ICU Stay (Mann-Whitney U Test) *p<0.05,**p<0.01 
Symbols denote a difference between Prolonged Hospital Stay vs Non-Prolonged Hospital Stay (Mann-Whitney U Test) †p<0.05,††p<0.01 
Symbols denote a difference between Prolonged Ventilation vs Non-Prolonged Ventilation (Mann-Whitney U Test) ‡p<0.05,‡‡p<0.01 
















Table 3 – Area Under the Receiver Operator Curve of suPAR and Logistic EuroScore II for each outcome 

































































Values presented are Area Under the Receiver Operator Curve with (95% Confidence Intervals)  
Values highlighted in bold are statistically significant p<0.05 
asuPAR and CRP beyond POD1 was not used to predict Prolonged ICU stay or prolonged ventilation as 
those patients still in ICU or still ventilated on POD2 automatically qualified in those categories 
PreOp = Preoperative; POD1, 2 or 3 = Postoperative days 1, 2 or 3 
